CN113425706A - Application of methyl eugenol in preparation of medicine for relieving renal ischemia reperfusion injury - Google Patents
Application of methyl eugenol in preparation of medicine for relieving renal ischemia reperfusion injury Download PDFInfo
- Publication number
- CN113425706A CN113425706A CN202110926422.1A CN202110926422A CN113425706A CN 113425706 A CN113425706 A CN 113425706A CN 202110926422 A CN202110926422 A CN 202110926422A CN 113425706 A CN113425706 A CN 113425706A
- Authority
- CN
- China
- Prior art keywords
- reperfusion injury
- methyl eugenol
- renal ischemia
- application
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 title claims abstract description 78
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229940116837 methyleugenol Drugs 0.000 title claims abstract description 33
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 24
- 206010063897 Renal ischaemia Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- -1 oral preparation Substances 0.000 claims description 2
- 230000006378 damage Effects 0.000 abstract description 11
- 208000027418 Wounds and injury Diseases 0.000 abstract description 9
- 208000014674 injury Diseases 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- 230000010410 reperfusion Effects 0.000 description 10
- 210000005084 renal tissue Anatomy 0.000 description 8
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010822 cell death assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of methyl eugenol in preparing a medicament for relieving renal ischemia-reperfusion injury, which comprises a medicinal composition containing the methyl eugenol and various pharmaceutically acceptable medicinal preparations of the methyl eugenol, has a protective effect on the renal ischemia-reperfusion injury, can relieve the injury, and has clinical practical significance and value for further development and application.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an application of methyl eugenol in preparing a medicine for relieving renal ischemia-reperfusion injury.
Background
The blood supply interruption can cause ischemic injury of tissues or organs, and the timely restoration of blood flow perfusion is helpful for preserving the functions of the tissues or organs. However, in some cases, reperfusion of tissue or organ blood flow can further exacerbate the injury, i.e., ischemia reperfusion injury (renal ischemia/reperfusion (I/R) injury is one of the most common clinical causes of acute renal injury AKI, manifested primarily as oxidative stress and inflammatory cell infiltration.) the main feature of renal I/R is reduced arterial blood supply to renal tissue, and reperfusion of blood flow causes further injury to renal tissue.
The natural compound Methyl Eugenol (ME), a substance structurally similar to eugenol, is an alkenylbenzene compound, has been detected in 450 various plants, many of which are used as a source of food, essential oils or drugs. The ten years of history that ME is used as a main component of a traditional Chinese medicine formula for tissue repair and wound healing has reported that the main target organ and metabolic site of rodent metabolic energy are livers. However, to date, no reports and description of ME for reducing renal ischemia reperfusion injury have been reported or described in the prior art.
Disclosure of Invention
In view of the defects of the prior art, the invention aims to provide the application of methyl eugenol in preparing the medicine for relieving renal ischemia-reperfusion injury.
The purpose of the invention is realized by the following technical scheme:
the invention aims to provide application of methyl eugenol in preparing a medicine for relieving renal ischemia-reperfusion injury.
Preferably, the drug is administered at a dose of not less than 3 mg/kg/day.
The invention also aims to provide application of the pharmaceutical composition containing the methyl eugenol in preparing the medicine for relieving the renal ischemia-reperfusion injury.
The invention also aims to provide a pharmaceutical preparation for relieving the renal ischemia-reperfusion injury, which comprises an injection, an oral preparation, a powder injection, a gel, a capsule and a patch; the content of methyl eugenol in the preparation is more than 80%.
The invention has the outstanding effects that:
the invention provides application of methyl eugenol in preparing a medicament for relieving renal ischemia-reperfusion injury, which comprises a medicinal composition containing the methyl eugenol and various pharmaceutically acceptable medicinal preparations of the methyl eugenol, has a protective effect on the renal ischemia-reperfusion injury, can relieve the injury, and has clinical practical significance and value for further development and application.
Drawings
FIG. 1A is a graph showing the results of measurement of Blood Urea Nitrogen (BUN) in the sham-operated group, IRI group, and IRI + ME group after 24 hours of reperfusion;
FIG. 1B is a graph showing the results of measurement of blood creatinine (Cr) in the sham-operated group, IRI group, and IRI + ME group after 24 hours of reperfusion;
FIG. 1C renal tissue H & E stained tissue image;
FIG. 2A is a kidney tissue image of a sham-operated group, IRI + ME group;
FIG. 2B is a graph showing the number of TUNEL positive cells in the sham, IRI, and IRI + ME groups;
FIG. 2C is a graph of the levels of Cas3, C-Cas3, and β -actin in the sham-operated, IRI + ME groups 24h after reperfusion;
FIG. 3 is a diagram showing the result of detecting apoptosis by flow cytometry;
FIG. 4 is a graph showing the results of measuring the ROS content in cells by using a DCFH-DA fluorescent probe.
Detailed Description
In order to clearly understand the technical features, objects and advantages of the present invention, the following detailed description of the technical solutions of the present invention is provided, but the technical solutions of the present invention are not to be construed as limiting the implementable scope of the present invention. The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials are commercially available, unless otherwise specified.
Example 1
1. Establishment of mouse kidney ischemia reperfusion (I/R) injury model
Male C57BL/6J mice (6-8 weeks old, 20-22 g body weight, Beijing HFK Bioscience) were selected for the experiments. Mice were randomly divided into Sham (Sham), IRI + ME groups. Mice were anesthetized by Intraperitoneal (IP) injection of 1% pentobarbital (80mg/kg body weight), core body temperature was maintained at 32 ℃ using a constant temperature blanket, after midline laparotomy, right renal pedicle was ligated under an IRI group microscope and right kidney was excised, left renal pedicle was closed with a microaneurysm clamp for 35min, the clamp was removed and the incision was sutured bilaterally. The sham operated group excised the right kidney without pinching the renal pedicle of the left kidney, and opened the abdomen for 30 min. After surgery, mice were allowed ad libitum access to food and water. Mice were sacrificed 24 hours after reperfusion. Plasma samples and kidney tissue were collected for experimental testing.
2. Results of the experiment
1) The experimental results of this example are shown in FIGS. 1A-1C.
(A) After 24 hours of reperfusion, the measurement results of Blood Urea Nitrogen (BUN) of Sham (Sham), IRI + ME groups were measured to check whether the urination function was normal.
(B) 24h after reperfusion, measurement results of blood creatinine (Cr) of Sham (Sham), IRI, and IRI + ME groups were measured to determine whether renal function was normal.
(C) Kidney tissue H & E was stained 200-fold at a scale bar of 50. mu.M. Renal injury was quantified using the Suzuki score.
The levels of BUN and Cr were significantly increased in the IRI group compared to the sham group, while the levels were significantly decreased in the IRI + ME group compared to the sham group. Pathological evaluation showed that the IRI group had severe kidney damage and increased necrotic area compared to the IRI + ME group, and was further quantified by suzuki scores. ME protects the kidney from ischemia reperfusion injury and protects renal function.
2) TUNEL method (deoxyribonucleotide terminal transferase mediated gap end labeling):
apoptosis in paraffin sections was assessed by TUNEL assay using an in situ cell death assay kit, POD (roche, basel, switzerland). Formalin-fixed and paraffin-embedded kidney tissue sections were dewaxed by washing in xylene and rehydrated by a series of progressive ethanol and distilled water. Enzymatic in situ labeling of DNA strand breaks was performed on proteinase K permeabilized sections using the TUNEL technique according to production instructions. Apoptosis was assessed using an Olympus BX-51 light microscope, 6 images were captured from randomly selected fields per section (fig. 2A), and the number of TUNEL positive cells was calculated (fig. 2B). As shown in fig. 2A-2C, the number of tunel-positive cells was significantly increased in the IRI group compared to the sham group; whereas after ME treatment the number of tunel positive cells decreased. In addition, IR increased expression of the apoptotic proteins Cas3, C-Cas3 and β -actin in renal tissue, which was significantly reversed after ME treatment (fig. 2C). From this it can be demonstrated that ME alleviates IRI induced apoptosis.
3) Inhibiting apoptosis of HK-2 cells following I/R injury
The cell apoptosis is detected by a flow cytometer by using double staining of phospholipid binding protein V (Annexin V) and Propidium Iodide (PI), as shown in figure 3, the result shows that HK-2 apoptotic cells in the I/R model group are obviously increased compared with those in the NC group; the IR + ME group can obviously reduce the apoptosis of the HK-2 cells and is dose-dependent, which indicates that the ME pretreatment can improve the I/R damage of the HK-2 cells and inhibit the apoptosis of the HK-2 cells.
4) Inhibition of ROS production in HK-2 cells following I/R injury
Detecting the ROS level in the cells by using a DCFH-DA fluorescent probe, as shown in figure 4, the result shows that the fluorescence intensity of the I/R model group is obviously higher than that of the NC group; the average fluorescence intensity of ROS in the IR + ME group is obviously lower than that in the I/R model group, which indicates that ME can inhibit the generation of ROS in cells after I/R injury.
5) In this example, acute protection experiments were performed using large doses of methyl eugenol for the renal ischemia-reperfusion injury model. 20mg/kg, 40mg/kg and 80mg/kg methyl eugenol is used for performing gastric perfusion on a renal ischemia-reperfusion injury model, after 12 hours, neutrophil infiltration is obviously inhibited, after 24 hours, the neutrophil infiltration keeps a better inhibition effect, meanwhile, under the administration dosage of 80mg/kg, the abnormal expression of poisoning of the model group is not found, which indicates that under the condition of large-dose administration, the inflammatory reaction of the kidney during IRI can be obviously relieved, the apoptosis caused by IRI is relieved, and under the condition of long-time non-administration, the effect can still be kept, thus the methyl eugenol in the specification can be used as a first-aid medicine for treating the renal ischemia-reperfusion injury, and the toxicity is very low.
In conclusion, in the kidney ischemia-reperfusion injury model, ME can protect the kidney from ischemia-reperfusion injury, relieve the inflammatory reaction of the kidney during IRI and relieve the apoptosis caused by IRI, so ME can be used for relieving the kidney ischemia-reperfusion injury.
Example 2
This example provides a pharmaceutical composition comprising methyl eugenol for reducing renal ischemia reperfusion injury. The pharmaceutical composition can also be prepared into acceptable pharmaceutical preparations, which comprise injections, oral preparations, powder injections, gels, capsules and patches; the content of methyl eugenol in the medicinal preparation is more than 80%.
Claims (4)
1. Application of methyl eugenol in preparing medicine for relieving renal ischemia reperfusion injury is provided.
2. Use according to claim 1, characterized in that: the administration dose of the medicine is not less than 3 mg/kg/day.
3. Application of a pharmaceutical composition containing methyl eugenol in preparing a medicament for relieving renal ischemia-reperfusion injury.
4. A pharmaceutical preparation for relieving renal ischemia reperfusion injury comprises injection, oral preparation, powder for injection, gel, capsule and patch; the content of methyl eugenol in the preparation is more than 80%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110926422.1A CN113425706A (en) | 2021-08-12 | 2021-08-12 | Application of methyl eugenol in preparation of medicine for relieving renal ischemia reperfusion injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110926422.1A CN113425706A (en) | 2021-08-12 | 2021-08-12 | Application of methyl eugenol in preparation of medicine for relieving renal ischemia reperfusion injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113425706A true CN113425706A (en) | 2021-09-24 |
Family
ID=77797610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110926422.1A Pending CN113425706A (en) | 2021-08-12 | 2021-08-12 | Application of methyl eugenol in preparation of medicine for relieving renal ischemia reperfusion injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113425706A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020128211A1 (en) * | 1998-02-06 | 2002-09-12 | Toshikazu Yoshikawa | Agent for preventing and curing hindrance of ischemic reperfusion |
| WO2006019187A1 (en) * | 2004-08-18 | 2006-02-23 | The University Of Tokyo | Remedy for renal disorder |
| CN1857534A (en) * | 2006-03-17 | 2006-11-08 | 四川省中药研究所 | Medicine composition for treating cardiac and cerebral vascular diseases |
| TW201821058A (en) * | 2016-12-02 | 2018-06-16 | 白藜蘆醇作者生技研發有限公司 | Chinese herbal medicine composition for caring epidermal stem cells of skin and having multiple functions and mask using the same having the effect of caring the epidermal stem cells of skin |
| CN111067888A (en) * | 2020-01-15 | 2020-04-28 | 桂林医学院附属医院 | Application of syringaresinol in preparation of medicine for preventing and treating liver ischemia reperfusion injury |
-
2021
- 2021-08-12 CN CN202110926422.1A patent/CN113425706A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020128211A1 (en) * | 1998-02-06 | 2002-09-12 | Toshikazu Yoshikawa | Agent for preventing and curing hindrance of ischemic reperfusion |
| WO2006019187A1 (en) * | 2004-08-18 | 2006-02-23 | The University Of Tokyo | Remedy for renal disorder |
| CN1857534A (en) * | 2006-03-17 | 2006-11-08 | 四川省中药研究所 | Medicine composition for treating cardiac and cerebral vascular diseases |
| TW201821058A (en) * | 2016-12-02 | 2018-06-16 | 白藜蘆醇作者生技研發有限公司 | Chinese herbal medicine composition for caring epidermal stem cells of skin and having multiple functions and mask using the same having the effect of caring the epidermal stem cells of skin |
| CN111067888A (en) * | 2020-01-15 | 2020-04-28 | 桂林医学院附属医院 | Application of syringaresinol in preparation of medicine for preventing and treating liver ischemia reperfusion injury |
Non-Patent Citations (5)
| Title |
|---|
| KUANG BC,ET AL: "Methyl eugenol protects the kidney from oxidative damage in mice by blocking the Nrf2 nuclear export signal through activation of the AMPK/GSK3β axis", ACTA PHARMACOL SIN, vol. 44, no. 02, pages 367 - 380 * |
| 刘启祥，等: "丁香酚对大鼠肾缺血再灌注性损伤保护作用的研究", 临床和实验医学杂志, vol. 16, no. 13, pages 1261 * |
| 匡柏成，等: "甲基丁香酚对人肾小管上皮细胞缺氧/复氧损伤的影响及其机制研究", 中国中药杂志, vol. 46, no. 24, pages 6502 - 6510 * |
| 匡柏成，等: "甲基丁香酚的生物学活性及其作用机制的研究进展", 现代药物与临床, vol. 36, no. 07, pages 1533 * |
| 李英超，等: "甲基丁香酚药理及毒理作用的研究进展", 中南药学, vol. 11, no. 09, pages 112 - 115 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boeing et al. | Luteolin prevents irinotecan‐induced intestinal mucositis in mice through antioxidant and anti‐inflammatory properties | |
| JP2013522311A (en) | Combination therapy with cyclosporine and aromatic-cationic peptide | |
| Jin et al. | Propofol limits rat myocardial ischemia and reperfusion injury with an associated reduction in apoptotic cell death in vivo | |
| Wei et al. | Gallic acid attenuates postoperative intra-abdominal adhesion by inhibiting inflammatory reaction in a rat model | |
| WO2005082349A1 (en) | Composition for the treatment of obesity comprising fumagillol derivative | |
| Yang et al. | Melatonin alleviates intestinal injury, neuroinflammation and cognitive dysfunction caused by intestinal ischemia/reperfusion | |
| Huang et al. | Curcumin inhibits the increase of glutamate, hydroxyl radicals and PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in rabbits | |
| KR100516827B1 (en) | Nitric Oxide Production Inhibitor | |
| BR112021001130A2 (en) | uses of pyrimidine compounds in the preparation of drugs to prevent or treat non-alcoholic steatohepatitis and liver fibrosis | |
| Li et al. | Maslinic acid attenuates ischemia/reperfusion injury-induced myocardial inflammation and apoptosis by regulating HMGB1-TLR4 axis | |
| US10945986B2 (en) | Treatment for ischemic stroke | |
| Li et al. | Poncirin ameliorates cardiac ischemia-reperfusion injury by activating PI3K/AKT/PGC-1α signaling | |
| CN113425706A (en) | Application of methyl eugenol in preparation of medicine for relieving renal ischemia reperfusion injury | |
| YANG et al. | Prevention of Cistanche salsa extract on hepatic fibrosis induced by carbon tetrachloride in rats | |
| Mahmoudieh et al. | The effect of Punica granatum L. flower extract on post-surgical peritoneal adhesions in a rat model | |
| Tanrıkulu et al. | Diosmin ameliorates intestinal injury induced by hepatic ischemia reperfusion in rats | |
| KR100626724B1 (en) | Extract of herbal mixture and pharmaceutical composition for prevention or treatment of liver fibrosis | |
| CN116077512A (en) | Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin | |
| Cüre et al. | Topiramate has protective effect on renal injury | |
| CN113398105A (en) | Application of methyl eugenol in preparation of medicine for relieving liver ischemia reperfusion injury | |
| Hu et al. | Mitoquinone treatment for the prevention of surgical adhesions via regulation of the NRF2/HO-1 signaling pathway in mice | |
| CN115463216A (en) | Combination drug for treating drug-induced liver injury induced by acetaminophen overdose | |
| JP7361448B2 (en) | Transglutaminase expression promoter | |
| Wang et al. | Saikosaponin A alleviates rat liver fibrosis by inhibiting Hedgehog signaling pathway-mediated autophagy and NLRP3 inflammasome | |
| Şahin et al. | The Effect of Different Doses of Amantadine on Lung Tissue In Hepatıc Ischemia Reperfusion Injury in Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210924 |